Patent SG-11201807526S-A (SG)
Title: Combination therapy using a liv1-adc and a chemotherapeutic
Inventor: SUSSMAN DJANGO
IPC: C07K16/30
Filed: 2017-03-15
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization MD 1111101110101011111 HO 1111101110111 1011 010111011101111111110111011# International Bureau ... .1 j (43) International Publication Date ..... ....!;,„. (10) International Publication Number WO 2017/161007 Al 21 September 2017 (21.09.2017) WIP0 I PCT (51) International Patent Classification: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, A61K 47/00 (2006.01) C07K 16/30 (2006.01) KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, A61K 47/55 (2017.01) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (21) International Application Number: RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, PCT/US2017/022541 TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (22) International Filing Date: ZA, ZM, ZW. 15 March 2017 (15.03.2017) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (26) Publication Language: English TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (30) Priority Data: TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, 62/308,639 15 March 2016 (15.03.2016) US DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, 62/317,792 4 April 2016 (04.04.2016) US LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, 62/367,510 27 July 2016 (27.07.2016) US SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (71) Applicant: SEATTLE GENETICS, INC. [US/US]; 21823 30th Drive SE, Bothell, Washington 98021 (US). Declarations under Rule 4.17: (72) Inventors: SUSSMAN, Django; 21823 30th Drive SE, as to applicant's entitlement to apply for and be granted a Bothell, Washington 98021 (US). LI, Fu; 21823 30th patent (Rule 4.17(ii)) _ Drive SE, Bothell, Washington 98021 (US). KOSTIC, — as to the applicant's entitlement to claim the priority of the — _ Ana; 21823 30th Drive SE, Bothell, Washington 98021 earlier application (Rule 4.17(iii)) (US). Published: (74) Agents: KELLY, Beth L. et al.; 21823 30th Drive SE, with international search report (Art. 21(3)) Bothell, Washington 98021 (US). — before the expiration of the time limit for amending the (81) Designated States (unless otherwise indicated, for every claims and to be republished in the event of receipt of kind of national protection available): AE, AG, AL, AM, amendments (Rule 48.2(h)) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, = BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, — with sequence listing part of description (Rule 5.2(a)) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, = = Title: COMBINATION THERAPY USING A LW1-ADC AND A CHEMOTHERAPEUTIC = (54) = LIVIA + Abraxane — = LIVIA + Doxorubicin ''' — loco = ,';loon- E E E E = 1 4 = 1 ‘7, > 500- 'a ,_ , ' `7! 500 o E FA 1 \"dra i I 1 - = g 1- . . , 1- .. . Fi E 0 ' .4r. — _ i 0 0 20 40 60 0 20 40 60 Days post implant - _ Days post implant -)E Untreated -X- Untreated 4- hLIV22-1006(4) 1 mg/kg q4dx4 ip 11 4- hLIV22-1006(4) 1 mg/kg q4dx4 ip -B- Abraxane 10 mg/kg q4dx3 ip -0- Doxorubicin 1 mg/kg q4dx3 iv -e- Abraxane 20 mg/kg q4dx3 ip 4 hLIV22-1006(4)1 mg/kg + Doxorubicin 1mg/kg Ir---- -I} hLIV22-1006(4) 1 mg/kg + Abraxane 10 mg/kg © Q- hLIV22-1006(4) 1 mg/kg + Abraxane 20 mg/kg © 11 - FIGURE 6 ---.... IN 1-1 (57) : The invention provides methods of treating a subject having or at risk of cancer by administering a LW-1 antibody 0 drug conjugate and a chemotherapeutic. el 0